Assess safety of intra-arterial autologous myogenic stem cell therapy for m.3243A>G mutation carriers

Completed

• Conditions: mitochondrial myopathy; mitochondrial muscular disease; 10028302

• Registration Number: NL-OMON50120
• Lead Sponsor: Medisch Universitair Ziekenhuis Maastricht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 15

Inclusion Criteria

Adult carriers of >40% m.3243A>G mutation in muscle

Exclusion Criteria

- Use of anti-coagulants, anti-thrombotics and other medication influencing
coagulation
- Have a weekly alcohol intake of >= 35 units (men) or >= 24 units (women)
- Current history of drug abuse
- Deficient immune system or autoimmune disease
- Significant concurrent illness
- Ongoing participation in other clinical trials
- Major surgery within 4 weeks of the visit
- Vaccination within 4 weeks of the visit
- Pregnant or lactating women
- Psychiatric or other disorders likely to impact on informed consent
- Patients unable and/or unwilling to comply with treatment and study
instructions
- Stokes
- Allergy for contrast fluid
- Peripheral signs of ischemia or vasculopathy
- Any other factor that in the opinion of the investigator excludes the patient
from the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified